The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

First-in-human evaluation of a novel balloon-expandable transcatheter heart valve in patients with severe symptomatic native aortic stenosis: the MyVal-1 study

EuroIntervention 2020;16:421-429. DOI: 10.4244/EIJ-D-19-00413

1. Mount Sinai Health System, New York, NY, USA; 2. Eternal Heart Care Centre & Research Institute Pvt. Ltd., Rajasthan, India; 3. Medanta - The Medicity, Haryana, India; 4. Sanjay Gandhi Post Graduate Institute of Medical Sciences, Uttar Pradesh, India; 5. Military Hospital Cardio Thoracic Centre, Maharashtra, India; 6. Christian Medical College & Hospital, Tamil Nadu, India; 7. Lokmanya Tilak Municipal Medical College & General Hospital, ­Maharashtra, India; 8. Narayana Institute of Cardiac Sciences, Karnataka, India; 9. Apollo Hospital Enterprise Limited, Tamil Nadu, India; 10. Sree Chitra Tirunal Institute for Medical Sciences & Technology, Kerala, India; 11. Sri Jayadeva Institute of Cardiovascular Sciences & Research, Karnataka, India; 12. G. Kuppuswamy Naidu Memorial Hospital, Tamil Nadu, India; 13. Lari Cardiology Centre, King George’s Medical University, Uttar Pradesh, India; 14. Fortis Escorts Heart Institute, New Delhi, India

Aims: The aim of this study was to demonstrate the safety and efficacy of the next-generation balloon-expandable Myval transcatheter heart valve (THV) in an intermediate- or high-risk patient population with severe symptomatic native aortic stenosis.

Methods and results: MyVal-1 was a first-in-human, prospective, multicentre, single-arm, open-label study. Between June 2017 and February 2018, a total of 30 patients were enrolled at 14 sites across India. Mean age was 75.5±6.7 years; 43.3% had coronary artery disease. The mean Society of Thoracic Surgeons score was 6.4±1.8% and 100% of the patients were in New York Heart Association (NYHA) functional Class II/III/IV pre-procedure. The six-minute walk test and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores were recorded. After successful implantation of the Myval THV, 96.6% and 100% were in NYHA functional Class I/II at 30-day and 12-month follow-up, respectively. Outcomes of the six-minute walk test (148.0±87.4 vs 336.0±202.9 m) and KCCQ score (36.6±11.0 vs 65.9±11.4) improved from baseline to 12-month follow-up. The effective orifice area (0.6±0.2 vs 1.8±0.3 cm2, p<0.0001), mean aortic valve gradient (47.4±8.8 vs 12.0±3.3 mmHg, p<0.0001), peak aortic valve gradient (71.7±13.0 vs 20.3±5.9 mmHg, p<0.0001) and transaortic velocity (4.5±0.4 vs 2.2±0.4 m/s, p<0.0001) improved substantially from baseline to 12 months post procedure. Four all-cause mortality cases were reported up to 12 months. Moreover, there was no other moderate/severe paravalvular leak, aortic regurgitation or need for new permanent pacemaker (PPM) up to 12-month follow-up.

Conclusions: The MyVal-1 study demonstrated the primary safety and efficacy of the Myval THV with no new PPM requirement up to 12-month follow-up. However, future trials with a larger number of patients and long-term follow-up are warranted to establish the safety and efficacy of the device.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Transcatheter aortic valve implantation after transcatheter mitral valve implantation